Abstract
The treatment landscape for advanced-stage Hodgkin lymphoma (HL) continues to evolve, with immune checkpoint inhibitors now pivotal to improving patient outcomes. One of the most promising developments is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This novel approach has demonstrated encouraging efficacy and is increasingly integrated into frontline treatment regimens. This article provides practical, evidence-based knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD. It reviews the most frequently observed adverse events, including immune-mediated events, and outlines best practices for monitoring and management. A real-world case study illustrates how proactive management and clinical judgment can influence outcomes in patients receiving nivolumab-AVD.
